Sivelestat sodium (SIV), a highly specific neutrophil elastase (NE) inhibitor, has been clinically used to treat ALI by inhibiting the activity of NE [22] and was marketed rapidly in China during the novel coronavirus disease 19 (COVID-19) epidemic in 2020. This evidence concerns the gene ELANE and acute respiratory distress syndrome.